BREA, Calif., Nov. 5, 2014 /PRNewswire/ -- HemoCue America, a leader in advanced point-of-care testing (POCT) systems, today announced delivery of HemoCue(® )White Blood Cell (WBC) Analyzers to a number of US hospitals. The WBC Analyzers are a part of emergency preparedness plans for handling of suspected Ebola patients.

Designed specifically for use in the determination of total white blood cell counts, the HemoCue(®) WBC System offers lab-accurate results at the point of care. "With the HemoCue(®) WBC System, a total white blood count can be obtained in just 3 minutes," said Josie Cunningham, Scientific Affairs Manager for HemoCue America. No calibration or instrument adjustment is required and the small device is portable for use in isolation areas where specimen contact must be restricted.

The WBC Analyzer is part of a broader point-of-care portfolio offered by HemoCue for use in physician offices and hospitals. "HemoCue America is pleased to be able to support the efforts of US hospitals, as they implement readiness processes to manage this deadly virus," said Josie Cunningham.

About HemoCue America

HemoCue America, a division of Radiometer America Inc. is a leader in advanced medical testing systems that bring lab-quality results to the point of care. Its leading products include hemoglobin, glucose, urine albumin and white blood cell point-of-care testing systems. The fundamental concept behind HemoCue products is the ability to perform common blood and urine tests at the point of care without sacrificing the accuracy and precision offered by a central clinical lab. These systems are portable and can be placed in remote or isolation areas with the benefits of sample containment, control and disposal.

For additional information about HemoCue America, visit http://www.hemocue.us.

SOURCE HemoCue America

SOURCE: HemoCue America